Online inquiry

IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8131MR)

This product GTTS-WQ8131MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8131MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11565MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ154MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ5099MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ8320MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ2255MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ14367MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ15925MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW